Press Releases
Media Library
Social Media
Corporate Brand
Analyst Coverage
Annual and Interim Reports
ANNUAL REPORT 2015
Broker Forecast
Email Alerts
Events
Financial Highlights
Investor News
NPS Pharma Acquisition
Our Strategy
Presentations and Webcasts
Quarterly Results
Shareholder Information
Stock Information
WHO WE ARE
Our Story
Responsibility
Leadership
How We Operate
PATIENTS
Patient Services
Patient Advocacy
Therapeutic Areas
Humanitarian Access
Improving Diagnosis
Scholarships
R&D
Our R&D Strategy
Collaborations
Pipeline
Clinical Trials
RESEARCH AND EDUCATIONAL GRANTS
PRODUCTS
Product List
Manufacturing
Postmarketing Commitments
CAREERS
Open Positions
US Internship Program
Culture And Values
Diversity And Inclusion
Learning and Development
Benefits
Dedicated to recognizing academic achievement in the rare disease community. Visit www.shireaces.com
Additional information about creating the global leader in rare diseases.
Visit www.rarediseaseleader.com
2015 Annual Responsibility Review Now Available
Download the PDF
Shire Marks 30th Anniversary with Innovative Global Program to Benefit Children with Rare Diseases Read more
Shire Moves Up 10 Positions on the Global 100 Sustainability Index.
Read more
A collection of videos designed to shine a light on some of the work—and partners—we are really proud of. Learn more
We’re joining forces to help Congenital Diaphragmatic Hernia (CDH) patients.
Visit our YouTube Channel
The Telethon Institute of Genetics and Medicine, Shire and the undeniable power of partnership.
Our employees get up each day with a belief in what we do, and the patients we do it for. We have open positions in locations around the globe.
Shire named the #1 most reputable healthcare company in the US.
Read about Courtney, Alex and Shawn, their positions, and what they love about Shire.
S06661 07/2015 | INTSP/C-ANPROM/CORP/15/0006
By following this link you will be leaving a Shire controlled website for a third party website. Please note that Shire is not responsible or liable for any third party website and the website may not be appropriate for all audiences.